COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Size: px
Start display at page:

Download "COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute"

Transcription

1 COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

2 What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis, comorbidities, management Asthma/COPD Overlap: phenotype, management Smoking cessation: pearls, electronic cigarettes

3 55 year old male, current smoker (25 pack year history), presents with several months of worsening dyspnea on exertion. Has a chronic cough which he attributes to smoking. Two colds this past year, took him weeks to recover from each episode. Your diagnosis: 1. Asthma 2. COPD 3. Asthma/COPD Overlap 4. Unable to determine

4 55 year old male, current smoker (25 pack year history), presents with several months of worsening dyspnea on exertion. Has a chronic cough which he attributes to smoking. Two colds this past year, took him weeks to recover from each episode. Your diagnosis: 1. Asthma 2. COPD 3. Asthma/COPD Overlap 4. Unable to determine

5 COPD: Spirometry is Required to Make the Diagnosis Assesses lung function by measuring expiratory volumes and flow rates Obtain spirometry on all patients with chronic cough, sputum production or dyspnea

6 COPD = Fixed Airflow Obstruction Airflow limitation that is irreversible or partially reversible with bronchodilator FEV1/FVC ratio < 0.70 or < LLN FEV1: measure of severity of airflow obstruction Spirometry is not recommended as screening tool

7

8 COPD and Smoking Majority of risk for developing COPD is from smoking (~80%) 15 to 20% of smokers develop clinically significant COPD Symptoms typically develop after 20 or more pack years Smokers lose lung function at an accelerated rate Quitting is beneficial at any age, more pronounced in earlier quitters Passive smoke exposure has been implicated as a cause of COPD (affects women > men) Kohansal et al. Am J Respir Crit Care Med 2009;180:3 10

9 81 year old female, never smoker, presents with several month history of dyspnea on exertion. No associated cough, wheeze or chest tightness. No history of asthma. No history of chronic respiratory illness as a child or adult. Homemaker. No significant second hand smoke exposure.

10

11 COPD in Never Smokers Up to 20% of patients with COPD More common in women Typically moderate to severe obstruction Additional risk factors: low BMI, low education level, history of asthma, severe respiratory infections in childhood Occupational exposures: organic dust, biomass fuel Chest 2011; 139(4):

12

13

14 COPD: Management Goal of treatment: to improve symptoms and exercise capacity, reduce exacerbations and hospitalizations Considerations for initial therapy: Symptoms FEV1 History of exacerbations Past exacerbation history is the best predictor of future flares

15 63 yo male, former smoker, new diagnosis of COPD. FEV1 75% predicted (mild obstruction). Reports occasional dyspnea. No history of COPD flare. Which of the following is indicated? 1. Short-acting bronchodilator 2. Short-acting bronchodilator and flu vaccine 3. Short-acting bronchodilator, flu vaccine, long-acting bronchodilator (LABA or LAMA) 4. Short-acting bronchodilator, flu vaccine, combination therapy (ICS/LABA)

16 63 yo male, former smoker, new diagnosis of COPD. FEV1 75% predicted (mild obstruction). Reports occasional dyspnea. No history of COPD flare. Which of the following is indicated? 1. Short-acting bronchodilator 2. Short-acting bronchodilator and flu vaccine 3. Short-acting bronchodilator, flu vaccine, long-acting bronchodilator (LABA or LAMA) 4. Short-acting bronchodilator, flu vaccine, combination therapy (ICS/LABA)

17 Short-Acting Bronchodilators (SABA)

18 Short-Acting Bronchodilators (SAMA)

19 57 yo female with COPD here to establish care. FEV1 60% predicted (moderate obstruction). Has noticed breathlessness during walking on a flat surface. No h/o flare. What is the recommended first-line inhaled therapy? 1. Short-acting bronchodilator 2. Inhaled steroids 3. Long-acting bronchodilator 4. Long-acting bronchodilator/inhaled steroid combination

20 57 yo female with COPD here to establish care. FEV1 60% predicted (moderate obstruction). Has noticed breathlessness during walking on a flat surface. No h/o flare. What is the recommended first-line inhaled therapy? 1. Short-acting bronchodilator 2. Inhaled steroids 3. Long-acting bronchodilator 4. Long-acting bronchodilator/inhaled steroid combination

21 COPD: Bronchodilators (BD) are Key Long-Acting Bronchodilators

22 Same patient, here for six month follow up visit. Went to urgent care two months ago, diagnosed with bronchitis. Given prednisone and antibiotics. Taking Tiotropium daily. Still breathless with activity. What is the best next step? 1. Continue long-acting bronchodilator, add combination therapy (ICS/LABA) 2. Switch from long-acting bronchodilator to combination therapy (ICS/LABA) 3. Switch from long-acting bronchodilator monotherapy to dual BD therapy (LABA/LAMA) 4. Continue long-acting BD and add ICS

23 Same patient, here for six month follow up visit. Went to urgent care two months ago, diagnosed with bronchitis. Given prednisone and antibiotics. Taking Tiotropium daily. Still breathless with activity. What is the best next step? 1. Continue long-acting bronchodilator, add combination therapy (ICS/LABA) 2. Switch from long-acting bronchodilator to combination therapy (ICS/LABA) 3. Switch from long-acting bronchodilator monotherapy to dual BD therapy (LABA/LAMA) 4. Continue long-acting BD and add ICS

24 FLAME trial LABA/LAMA vs. ICS/LABA 17% reduction in moderate-to-severe exacerbations with dual bronchodilator therapy

25 Dual Bronchodilators (LABA/LAMA)

26 COPD: When to Think About Inhaled Steroids Moderate to severe COPD Repeated exacerbations Low quality of life Asthma-COPD Overlap Always in combination with LABA Risks associated with use: Oral candidiasis, hoarseness Skin bruising Pneumonia

27

28 Which of the following has been shown to impact survival in COPD? 1. Smoking cessation 2. Oxygen therapy (in patients with severe chronic resting hypoxemia) 3. Maintenance medication 4. 1 and 2 5. All of the above

29 Which of the following has been shown to impact survival in COPD? 1. Smoking cessation 2. Oxygen therapy (in patients with severe chronic resting hypoxemia) 3. Maintenance medication 4. 1 and 2 5. All of the above

30 Pulmonary Rehab Improves dyspnea and exercise capacity Reduces hospitalization and improves QOL in patients with a recent exacerbation What your patients should expect: Exercise training Education Inspiratory muscle training

31 COPD Exacerbations: Ambulatory Management GOLD 2017: worsening of respiratory symptoms that result in additional therapy Give antibiotics Infection implied in up to 80% of episodes Shortened recovery time, reduces treatment failure, increases time between flares Give oral steroids Improve lung function, trend toward fewer hospitalizations Dosage? Duration? (no more than 10 to 14 days) Anthonisen NR et al. Ann Intern Med 1987;106:196 Wedzicha et al. ERJ 2017; 49: Sethi S. Chest 2000;117:380S-385S

32 COPD Exacerbations: Antibiotic Selection Anzueto A et al. Am J Med Sci 2010; 340(4): Used with permission courtesy of Dr. Aboussouan

33 COPD: When to Refer Disease onset < 40 years old Frequent exacerbations (> 2 or more per year) despite therapy Severe airflow obstruction (FEV1 < 50%) Patients on oxygen therapy Significant comorbidities Considering add-on therapy

34 Asthma

35 What percent of study participants with physician-diagnosed asthma had no evidence of current asthma (% of patients in whom asthma was ruled out)? 1. 10% 2. 20% 3. 30% 4. 50% 5. 60% Aaron et al. JAMA. 2017; 317(3):

36 What percent of study participants with physician-diagnosed asthma had no evidence of current asthma (% of patients in whom asthma was ruled out)? 1. 10% 2. 20% 3. 30% 4. 50% 5. 60% Aaron et al. JAMA. 2017; 317(3):

37 Asthma: Diagnosis Chronic airway inflammation shortness of breath, cough, wheezing, chest tightness Variable symptoms (episodic) Variable airflow limitation Symptoms vary over time and in intensity

38 Airflow Obstruction with Positive Bronchodilator Response

39 Asthma: Diagnosis Whenever possible, confirm diagnosis before starting controller therapy Clinical urgency or other diagnosis unlikely start empiric treatment Then diagnostic testing within 1 to 3 months

40 Asthma Triggers

41 Your patient has a clinical history suggestive of asthma. You order lung function testing and it is normal, no reversibility. What is the best next step? 1. Consider alternative diagnosis 2. Treat empirically for asthma 3. Order methacholine challenge test 4. Check exhaled nitric oxide

42 Your patient has a clinical history suggestive of asthma. You order lung function testing and it is normal, no reversibility. What is the best next step? 1. Consider alternative diagnosis 2. Treat empirically for asthma 3. Order methacholine challenge test 4. Check exhaled nitric oxide

43 Methacholine Challenge Test

44 Exhaled Nitric Oxide (eno, FENO) > 50 ppb: eosinophilic airway inflammation High eno suggests steroid responsiveness Useful in monitoring inflammation 20% reduction = steroid responsiveness Assessment tool for adherence Not a good diagnostic test for asthma Also elevated in rhinosinusitis/atopy, eosinophilic bronchitis, COPD, eczema

45 Asthma is Heterogenous

46 Asthma Phenotypes Allergic asthma Non-allergic asthma Late-onset asthma Asthma with fixed airflow obstruction Asthma with obesity

47 Your patient has allergic asthma and you tell him the cat is a major trigger. He tells you his girlfriend will break up with him before she gets rid of the cat. Which of the following are strategies to reduce exposure? 1. Remove carpets/hepa filter on vacuum 2. Brush pet outside to remove dander 3. Remove the cat from the bedroom 4. Change your clothes after prolonged exposure to the animal 5. All of the above

48 Your patient has allergic asthma and you tell him the cat is a major trigger. He tells you his girlfriend will break up with him before she gets rid of the cat. Which of the following are strategies to reduce exposure? 1. Remove carpets/hepa filter on vacuum 2. Brush pet outside to remove dander 3. Remove the cat from the bedroom 4. Change your clothes after prolonged exposure to the animal 5. All of the above

49 Which of the following is the most common cause of uncontrolled asthma: 1. Poor adherence 2. Incorrect inhaler technique 3. Incorrect diagnosis 4. Inadequate therapy 5. Persistent exposure to triggers

50 Which of the following is the most common cause of uncontrolled asthma: 1. Poor adherence 2. Incorrect inhaler technique 3. Incorrect diagnosis 4. Inadequate therapy 5. Persistent exposure to triggers

51 Asthma Management: High Value, Low Cost Increase delivery of drug into the lung Increased potency of inhaled steroids Reduction in oropharyngeal candidiasis Toogood et al. AJRCCM 1984; 129:

52 Asthma Management: Anti-Inflammatory is the Standard

53 Combination Therapy: ICS/LABA

54 Asthma Management: Additional Therapies Anti-leukotrienes: Montelukast (Singulair ), Zafirlukast (Accolate ), Zileuton (Zyflo ) Biologic agents/monoclonal antibody: Omalizumab (Xolair ), Mepolizumab (Nucala ), Reslizumab (Cinqair ) Long-acting muscarinic antagonist (LAMA): Tiotropium (Spiriva )

55 Stepwise Approach to Asthma Therapy: Key Points Step 1: consider low dose ICS SABA alone for pts with asthma sxs less than twice/month, no nighttime sxs, no risks/hx flares ICS reduce risk of severe exacerbations Step 2: low dose ICS other options: LTRA, low dose theophylline Before considering step-up to 3 or 4: Check diagnosis, inhaler technique, exposures, adherence

56 Stepwise Approach to Asthma Therapy: Key Points Step 3: low dose ICS/LABA other options: med/high dose ICS OR low dose ICS + LTRA) Step 4: med/high dose ICS/LABA (add tiotropium) Step 5: refer for add-on treatment Step 3 to 5 reliever therapy: SABA or low dose ICS/LABA

57 Reddel et al. Eur Respir J 2015; 46:

58 >= 20 : well controlled : not well controlled 15 : very poorly controlled Asthma Control Test QualityMetric incorporated,

59 Asthma Management: Assess for Comorbidities Upper airway disease: chronic rhinosinusitis, nasal polyposis Obstructive sleep apnea GERD (no role for treatment if patient asymptomatic) Paradoxical vocal fold motion (formally known as vocal cord dysfunction) Obesity Depression

60 Asthma-COPD Overlap Nearly 25% of patients with COPD report history of asthma Features of both: more symptoms, increased rate of exacerbations, more likely hospitalized, more rapid decline lung function Younger, women men, higher BMI, fewer pack years of smoking, greater % African- Americans Compared to COPD alone: similar lung function, less emphysema on imaging Eur Respir J 2014; 44:

61 Asthma-COPD Overlap Suggested criteria Age > 40 FEV1/FVC < 0.70 Exposure to cigarette smoke Previous/current history of asthma/atopy Marked bronchodilator response (>400 ml) IgE level > 100 Blood eosinophils > 5% Treatment response is different Early initiation of inhaled corticosteroids is recommended Chest. 2015; doi: /chest

62 Your patient is interested in quitting smoking. Which of the following treatment methods has the highest abstinence rate? 1. Nicotine patch 2. Nicotine patch + nicotine gum 3. Buproprion SR (Zyban) 4. Nicotine patch + Buproprion 5. Varencycline (Chantix)

63 Your patient is interested in quitting smoking. Which of the following treatment methods has the highest abstinence rate? 1. Nicotine patch 2. Nicotine patch + nicotine gum 3. Buproprion SR (Zyban) 4. Nicotine patch + Buproprion 5. Varencycline (Chantix)

64 Your patient is overweight and concerned about weight gain after smoking cessation. Which of the following would be a good option? 1. Nicotine patch 2. Nicotine patch + nicotine gum 3. Buproprion SR (Zyban) 4. Nicotine patch + Buproprion 5. Varencycline (Chantix)

65 Your patient is overweight and concerned about weight gain after smoking cessation. Which of the following would be a good option? 1. Nicotine patch 2. Nicotine patch + nicotine gum 3. Buproprion SR (Zyban) 4. Nicotine patch + Buproprion 5. Varencycline (Chantix)

66 Electronic Cigarettes Most popular tobacco product among high school and middle school students Highest prevalence (14%) in young adults 18 to 24 years old

67 The Power of Advertising Perceived as a tool to quit or reduce smoking Similar efficacy to nicotine replacement therapy

68 Electronic Cigarettes: Lack of Evidence of Harm Safety Normalization of smoking behavior Gateway to other tobacco products Students identify use of e-cigarettes as a significant factor in being likely to try tobacco products Known pulmonary toxicity FDA now has authority to prohibit sale to minors

69 Thank You!

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype

More information

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation

More information

Asthma COPD Overlap (ACO)

Asthma COPD Overlap (ACO) Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma

More information

Biologic Agents in the treatment of Severe Asthma

Biologic Agents in the treatment of Severe Asthma Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human

More information

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Global Initiative for Asthma (GINA) What s new in GINA 2017? Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome

More information

Current Approaches to Asthma & COPD

Current Approaches to Asthma & COPD 10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:

More information

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University

More information

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

COPD. Helen Suen & Lexi Smith

COPD. Helen Suen & Lexi Smith COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters

Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

(Asthma) Diagnosis, monitoring and chronic asthma management

(Asthma) Diagnosis, monitoring and chronic asthma management Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic

More information

Asma e BPCO: le strategie terapeutiche

Asma e BPCO: le strategie terapeutiche Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive

More information

RESPIRATORY CARE IN GENERAL PRACTICE

RESPIRATORY CARE IN GENERAL PRACTICE RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly

More information

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

COPD/Asthma. Prudence Twigg, AGNP

COPD/Asthma. Prudence Twigg, AGNP COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

Changing Landscapes in COPD New Zealand Respiratory Conference

Changing Landscapes in COPD New Zealand Respiratory Conference Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview

More information

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017 GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and

More information

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80) Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D. Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma

More information

COPD or not COPD, that is the question.

COPD or not COPD, that is the question. COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP

More information

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. 10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough

More information

7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)

7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test) Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction

More information

CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA

CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to

More information

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

How to distinguish between uncontrolled and severe asthma

How to distinguish between uncontrolled and severe asthma How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct

More information

Integrated Cardiopulmonary Pharmacology Third Edition

Integrated Cardiopulmonary Pharmacology Third Edition Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive

More information

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease

More information

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other

More information

Difficult Asthma Assessment: A systematic approach

Difficult Asthma Assessment: A systematic approach Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia

More information

Global Initiative for Asthma (GINA) What s new in GINA 2016?

Global Initiative for Asthma (GINA) What s new in GINA 2016? Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple

More information

Asthma in Day to Day Practice

Asthma in Day to Day Practice Asthma in Day to Day Practice VIJAY.K.VANAM Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital

Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October

More information

ASTHMA. Dr Liz Gamble BRI

ASTHMA. Dr Liz Gamble BRI ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness

More information

Guideline for the Diagnosis and Management of COPD

Guideline for the Diagnosis and Management of COPD Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially

More information

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more. COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production

More information

I have no perceived conflicts of interest or commercial relationships to disclose.

I have no perceived conflicts of interest or commercial relationships to disclose. ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts

More information

Treatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology

Treatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the

More information

Asthma 2015: Establishing and Maintaining Control

Asthma 2015: Establishing and Maintaining Control Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26

More information

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D.

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing

More information

Do We Need Biologics in Pediatric Asthma Management?

Do We Need Biologics in Pediatric Asthma Management? Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor

More information

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical

More information

Disclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network

Disclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San

More information

Chronic Obstructive Pulmonary Disease Guidelines and updates

Chronic Obstructive Pulmonary Disease Guidelines and updates Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United

More information

COPD in primary care: reminder and update

COPD in primary care: reminder and update COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice

More information

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Drug Prior Authorization Guideline NUCALA (mepolizumab) Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and

More information

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Anyone who smokes and/or has shortness of breath and sputum production could have COPD COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough

More information

Asthma ASTHMA. Current Strategies for Asthma and COPD

Asthma ASTHMA. Current Strategies for Asthma and COPD Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,

More information

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma. ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma

More information

Improving the Management of Asthma to Improve Patient Adherence and Outcomes

Improving the Management of Asthma to Improve Patient Adherence and Outcomes Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in

More information

Asthma Update I have no professional or personal financial conflicts of interest to disclose.

Asthma Update I have no professional or personal financial conflicts of interest to disclose. Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have

More information

Asthma Update Jennifer W. McCallister, MD, FACP, FCCP

Asthma Update Jennifer W. McCallister, MD, FACP, FCCP Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS

COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was

More information

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,

More information

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.

More information

Asthma in the Athlete

Asthma in the Athlete Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT

WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures I have no actual

More information

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Blue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary

Blue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary Blue, Pink and everything in between: an update on COPD Tara Lohmann MD FRCPC Division of Respirology University of Calgary Disclosures I have eaten lunches provided by many pharmaceutical companies (GSK,

More information

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH

More information

Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute

Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute Exercise-Induced Bronchospasm Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute EIB Episodic bronchoconstriction with exercise May be an exacerbation

More information

Overview of COPD INTRODUCTION

Overview of COPD INTRODUCTION Overview of COPD INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a common lung disease that affects millions of people, and it is the fourth leading cause of death in the United States. It

More information

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management

More information

Potential risks of ICS use

Potential risks of ICS use Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk

More information